Saverio Bettuzzi

List of Publications by Year
in descending order

85 papers	8,589 citations	101496 36 h-index	58549 82 g-index
87 all docs	87 docs citations	87 times ranked	17283 citing authors

#	Article	IF	Citations
1	The Potential of Epigallocatechin Gallate (EGCG) in Targeting Autophagy for Cancer Treatment: A Narrative Review. International Journal of Molecular Sciences, 2022, 23, 6075.	1.8	27
2	Lemur Tyrosine Kinases and Prostate Cancer: A Literature Review. International Journal of Molecular Sciences, 2021, 22, 5453.	1.8	2
3	Efficacy of a Polyphenolic, Standardized Green Tea Extract for the Treatment of COVID-19 Syndrome: A Proof-of-Principle Study. Covid, 2021, 1, 2-12.	0.7	21
4	The Down-Regulation of Clusterin Expression Enhances the Î±Synuclein Aggregation Process. International Journal of Molecular Sciences, 2020, 21, 7181.	1.8	17
5	Effects of Standardized Green Tea Extract and Its Main Component, EGCG, on Mitochondrial Function and Contractile Performance of Healthy Rat Cardiomyocytes. Nutrients, 2020, 12, 2949.	1.7	6
6	Basic and applied science at the time of COVIDâ€19. FEBS Letters, 2020, 594, 2933-2934.	1.3	1
7	Flavonoids as Epigenetic Modulators for Prostate Cancer Prevention. Nutrients, 2020, 12, 1010.	1.7	39
8	N-Myc-mediated epigenetic reprogramming in advanced prostate cancer: personalized medicine and quality of biological samples. Translational Cancer Research, 2019, 8, S639-S641.	0.4	0
9	Clusterin Silencing in Prostate Cancer Induces Matrix Metalloproteinases by an NF-<i>Îº</i>B-Dependent Mechanism. Journal of Oncology, 2019, 2019, 1-12.	0.6	9
10	Molecular Targets of Epigallocatechinâ€”Gallate (EGCG): A Special Focus on Signal Transduction and Cancer. Nutrients, 2018, 10, 1936.	1.7	193
11	Clusterin. , 2018, , 341-349.		5
12	Long-Term Oral Administration of Theaphenon-E Improves Cardiomyocyte Mechanics and Calcium Dynamics by Affecting Phospholamban Phosphorylation and ATP Production. Cellular Physiology and Biochemistry, 2018, 47, 1230-1243.	1.1	12
13	Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges. Antioxidants, 2017, 6, 26.	2.2	35
14	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
15	Clusterin. , 2016, , 1100-1104.		0
16	EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism. Scientific Reports, 2015, 5, 15270.	1.6	56
17	Control of Autophagy in Cancer. BioMed Research International, 2015, 2015, 1-2.	0.9	4
18	Distinct promoters, subjected to epigenetic regulation, drive the expression of two clusterin mRNAs in prostate cancer cells. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 44-54.	0.9	19

#	Article	IF	Citations
19	Polyphenon EÂ®, a standardized green tea extract, induces endoplasmic reticulum stress, leading to death of immortalized PNT1a cells by anoikis and tumorigenic PC3 by necroptosis. Carcinogenesis, 2014, 35, 828-839.	1.3	58
20	Clusterin. , 2014, , 1-5.		0
21	Prognostic role of clusterin in resected adenocarcinomas of the lung. Lung Cancer, 2013, 79, 294-299.	0.9	17
22	Human Prostate Cancer Prevention by Green Tea Catechins. , 2013, , 1129-1144.		0
23	Anticancer Activity of Green Tea Polyphenols in Prostate Gland. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-18.	1.9	47
24	<i>mdaâ€•7</i>/ILâ€•24 differentially regulates soluble and nuclear clusterin in prostate cancer. Journal of Cellular Physiology, 2012, 227, 1805-1813.	2.0	33
25	Health Benefits of Tea. Oxidative Stress and Disease, 2011, , 239-261.	0.3	25
26	Chronic administration of green tea extract to TRAMP mice induces the collapse of Golgi apparatus in prostate secretory cells and results in alterations of protein post-translational processing. International Journal of Oncology, 2011, 39, 1521-7.	1.4	14
27	Molecular mechanisms of the antimetastatic activity of nuclear clusterin in prostate cancer cells. International Journal of Oncology, 2011, 39, 225-34.	1.4	8
28	Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel. Tumor Biology, 2011, 32, 1031-1047.	0.8	24
29	Upregulation of Clusterin in Prostate and DNA Damage in Spermatozoa from Bisphenol Aâ€"Treated Rats and Formation of DNA Adducts in Cultured Human Prostatic Cells. Toxicological Sciences, 2011, 122, 45-51.	1.4	61
30	The clusterin paradigm in prostate and breast carcinogenesis. Endocrine-Related Cancer, 2010, 17, R1-R17.	1.6	93
31	Regulation of CLU Gene Expression by Oncogenes and Epigenetic Factors. Advances in Cancer Research, 2009, 105, 115-132.	1.9	40
32	Clusterin, a Haploinsufficient Tumor Suppressor Gene in Neuroblastomas. Journal of the National Cancer Institute, 2009, 101, 663-677.	3.0	87
33	Clusterin is a short halfâ€•life, polyâ€•ubiquitinated protein, which controls the fate of prostate cancer cells. Journal of Cellular Physiology, 2009, 219, 314-323.	2.0	43
34	Epigenetic DNA-(cytosine-5-carbon) modifications: 5-aza-2â€²-deoxycytidine and DNA-demethylation. Biochemistry (Moscow), 2009, 74, 613-619.	0.7	48
35	Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread. Oncogene, 2009, 28, 4344-4352.	2.6	42
36	Clusterin (CLU) and Prostate Cancer. Advances in Cancer Research, 2009, 105, 1-19.	1.9	34

#	Article	IF	Citations
37	Chapter 1 Introduction. Advances in Cancer Research, 2009, 104, 1-8.	1.9	23
38	Chapter 2 Clusterin (CLU). Advances in Cancer Research, 2009, 104, 9-23.	1.9	43
39	Chapter 3 The Shifting Balance Between CLU Forms During Tumor Progression. Advances in Cancer Research, 2009, 104, 25-32.	1.9	8
40	Chapter 5 Nuclear CLU (nCLU) and the Fate of the Cell. Advances in Cancer Research, 2009, 104, 59-88.	1.9	24
41	Clusterin (CLU) and Lung Cancer. Advances in Cancer Research, 2009, 105, 63-76.	1.9	40
42	Conclusions and Perspectives. Advances in Cancer Research, 2009, 105, 133-150.	1.9	11
43	Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development. Cancer and Metastasis Reviews, 2008, 27, 315-334.	2.7	89
44	Chemoprevention of Human Prostate Cancer by Green Tea Catechins: Two Years Later. A Follow-up Update. European Urology, 2008, 54, 472-473.	0.9	147
45	A Novel Gene Signature for Molecular Diagnosis of Human Prostate Cancer by RT-qPCR. PLoS ONE, 2008, 3, e3617.	1.1	44
46	Creating prodynorphin-expressing stem cells alerted for a high-throughput of cardiogenic commitment. Regenerative Medicine, 2007, 2, 193-202.	0.8	8
47	Clusterin Isoforms Differentially Affect Growth and Motility of Prostate Cells: Possible Implications in Prostate Tumorigenesis. Cancer Research, 2007, 67, 10325-10333.	0.4	53
48	B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: Implications for cell survival. Blood Cells, Molecules, and Diseases, 2007, 39, 263-271.	0.6	11
49	Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer. Molecular Oncology, 2007, 1, 196-204.	2.1	22
50	Establishment of an organotypic in vitro culture system and its relevance to the characterization of human prostate epithelial cancer cells and their stromal interactions. Pathology Research and Practice, 2007, 203, 209-216.	1.0	13
51	Epigenetic DNA-methylation regulation of genes coding for lipid raft-associated components: a role for raft proteins in cell transformation and cancer progression (review). Oncology Reports, 2007, 17, 1279-90.	1.2	45
52	Chemoprevention of Human Prostate Cancer by Oral Administration of Green Tea Catechins in Volunteers with High-Grade Prostate Intraepithelial Neoplasia: A Preliminary Report from a One-Year Proof-of-Principle Study. Cancer Research, 2006, 66, 1234-1240.	0.4	744
53	Nuclear clusterin accumulation during heat shock response: Implications for cell survival and thermo-tolerance induction in immortalized and prostate cancer cells. Journal of Cellular Physiology, 2006, 207, 208-219.	2.0	37
54	Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling. Carcinogenesis, 2006, 27, 1047-1053.	1.3	31

#	Article	IF	Citations
55	Ca2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death and Differentiation, 2005, 12, 101-104.	5.0	44
56	Spermidine/spermine N 1 -acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N 1 ,N 12 -bis(ethyl)spermine and to cisplatin. Carcinogenesis, 2005, 26, 1677-1686.	1.3	14
57	Intracellular Clusterin Induces G2-M Phase Arrest and Cell Death in PC-3 Prostate Cancer Cells1. Cancer Research, 2004, 64, 6174-6182.	0.4	97
58	Clusterin-Mediated Apoptosis Is Regulated by Adenomatous Polyposis Coli and Is p21 Dependent but p53 Independent. Cancer Research, 2004, 64, 7412-7419.	0.4	74
59	The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis, 2004, 25, 2217-2224.	1.3	126
60	Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. British Journal of Cancer, 2004, 91, 1842-1850.	2.9	66
61	Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. International Journal of Cancer, 2004, 108, 23-30.	2.3	96
62	Cisplatin-resistance modulates the effect of protein synthesis inhibitors on spermidine/spermine N1-acetyltransferase expression. International Journal of Biochemistry and Cell Biology, 2004, 36, 123-137.	1.2	9
63	Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. European Journal of Endocrinology, 2004, 150, 591-603.	1.9	79
64	Cell detachment and apoptosis induction of immortalized human prostate epithelial cells are associated with early accumulation of a 45ÂkDa nuclear isoform of clusterin. Biochemical Journal, 2004, 382, 157-168.	1.7	53
65	Nuclear Translocation of a Clusterin Isoform Is Associated with Induction of Anoikis in SV40-Immortalized Human Prostate Epithelial Cells. Annals of the New York Academy of Sciences, 2003, 1010, 514-519.	1.8	35
66	Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study. Cancer Research, 2003, 63, 3469-72.	0.4	21
67	The new anti-oncogene clusterin and the molecular profiling of prostate cancer progression and prognosis. Acta Biomedica, 2003, 74, 101-4.	0.2	3
68	Estrogens, But Not Androgens, Regulate Expression and Functional Activity of Oxytocin Receptor in Rabbit Epididymis. Endocrinology, 2002, 143, 4271-4280.	1.4	69
69	Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene, 2002, 21, 4328-4334.	2.6	79
70	Manipulation of the expression of regulatory genes of polyamine metabolism results in specific alterations of the cell-cycle progression. Biochemical Journal, 2001, 354, 217-223.	1.7	35
71	Manipulation of the expression of regulatory genes of polyamine metabolism results in specific alterations of the cell-cycle progression. Biochemical Journal, 2001, 354, 217.	1.7	22
72	Increased levels of clusterin (SGP-2) mRNA and protein accompany rat ventral prostate involution following finasteride treatment. Journal of Endocrinology, 2000, 167, 197-204.	1.2	20

#	Article	IF	Citations
73	Coordinate changes of polyamine metabolism regulatory proteins during the cell cycle of normal human dermal fibroblasts. FEBS Letters, 1999, 446, 18-22.	1.3	54
74	Clusterin (SGP-2) gene expression is cell cycle dependent in normal human dermal fibroblasts. FEBS Letters, 1999, 448, 297-300.	1.3	22
75	Heparin inhibits phorbol ester-induced ornithine decarboxylase gene expression in endothelial cells. FEBS Letters, 1998, 423, 98-104.	1.3	9
76	Different localization of spermidine/spermine N1 -acetyltransferase and ornithine decarboxylase transcripts in the rat kidney. FEBS Letters, 1995, 377, 321-324.	1.3	18
77	Increased levels of clusterin mRNA in the ventral prostate of the aging rat are associated to increases in cuboidal (atrophic) cell population and not to changes in apoptotic activity. Biochemistry and Cell Biology, 1994, 72, 515-521.	0.9	24
78	Gene relaxation and aging: Changes in the abundance of rat ventral prostate SGP-2 (clusterin) and ornithine decarboxylase mRNAs. FEBS Letters, 1994, 348, 255-258.	1.3	19
79	Increases in sulphated glycoprotein-2 mRNA levels in the rat brain after transient forebrain ischemia or partial mesodiencephalic hemitransection. Molecular Brain Research, 1993, 18, 163-177.	2.5	22
80	Senescence, Immortalization, and Apoptosis.. Annals of the New York Academy of Sciences, 1992, 673, 70-82.	1.8	30
81	SGP-2, Apoptosis, and Aging. Annals of the New York Academy of Sciences, 1992, 663, 471-474.	1.8	13
82	Studies on the relationship between cell proliferation and cell death: Opposite patterns of SGP-2 and ornithine decarboxylase mRNA accumulation in pha-stimulated human lymphocytes. Biochemical and Biophysical Research Communications, 1991, 180, 59-63.	1.0	37
83	The gene for SP-40,40, human homolog of rat sulfated glycoprotein 2, rat clusterin, and rat testosterone-repressed prostate message 2, maps to chromosome 8. Genomics, 1991, 10, 151-156.	1.3	70
84	Regional increases in ornithine decarboxylase mRNA levels in the rat brain after partial mesodiencephalic hemitransection as revealed by in situ hybridization histochemistry. Neurochemistry International, 1991, 18, 347-352.	1.9	18
85	In vivo accumulation of sulfated glycoprotein 2 mRNA in rat thymocytes upon dexamethasone-induced cell death. Biochemical and Biophysical Research Communications, 1991, 175, 810-815.	1.0	91